E-LIB Suche - Ergebnisse für: Greil, R.

1

Impact of individualized treatment on recovery from fatigue..:

Ferdinandus, J. ; Müller, H. ; Damaschin, C....
Annals of Oncology. 35 (2024) 3 - p. 276-284 , 2024

Link: https://doi.org/10.1016/..

2

111MO Tailored dose-dense versus standard adjuvant chemothe..:

Foukakis, T. ; Matikas, A. ; Möbus, V....
ESMO Open. 9 (2024) - p. 103099 , 2024

Link: https://doi.org/10.1016/..

3

74P Real-world progression-free and overall survival of pat..:

Koopman, M. ; Garcia-Carbonero, R. ; Pinto, C....
Annals of Oncology. 35 (2024) - p. S36 , 2024

Link: https://doi.org/10.1016/..

4

Health-Related Quality of Life (HRQoL) Data From KEYNOTE-41..:

Machiels, J.P. ; TAO, Y. ; Burtness, B....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e39-e40 , 2024

Link: https://doi.org/10.1016/..

5

Comment on: Incidence, clinicopathological features, and cl..:

Huemer, F. ; Weiss, L. ; Regitnig, P....
ESMO Open. 9 (2024) 4 - p. 102973 , 2024

Link: https://doi.org/10.1016/..

6

PD-L1 and IRF1 expression is associated with improved thera..:

Heber, U. ; Hlauschek, D. ; Singer, C....
European Journal of Cancer. 200 (2024) - p. 113818 , 2024

Link: https://doi.org/10.1016/..

7

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANC..:

Borchmann, P. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 881-882 , 2023

Link: https://doi.org/10.1002/..

8

How I treat diffuse large B-cell lymphoma:

Melchardt, T. ; Egle, A. ; Greil, R.
ESMO Open. 8 (2023) 1 - p. 100750 , 2023

Link: https://doi.org/10.1016/..

9

106P Treatment sequencing in PD-L1–positive recurrent/metas..:

Greil, R. ; Burtness, B. ; Laban, S....
Immuno-Oncology and Technology. 20 (2023) - p. 100578 , 2023

Link: https://doi.org/10.1016/..

10

S-1 maintenance therapy in Caucasian patients with metastat..:

Stocker, G. ; Lorenzen, S. ; Ettrich, T....
ESMO Open. 8 (2023) 3 - p. 101572 , 2023

Link: https://doi.org/10.1016/..

11

Toxicities at one year follow‐up in patients with advanced ..:

Ferdinandus, J. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 363-364 , 2023

Link: https://doi.org/10.1002/..

12

123O Randomized phase II trial of neoadjuvant atezolizumab ..:

Rinnerthaler, G. ; Egle, D. ; Bartsch, R....
ESMO Open. 8 (2023) 1 - p. 101462 , 2023

Link: https://doi.org/10.1016/..

13

260MO Long-term patient-reported outcomes in premenopausal ..:

Bjelic-Radisic, V. ; Egle, D. ; Wette, V....
ESMO Open. 8 (2023) 1 - p. 101356 , 2023

Link: https://doi.org/10.1016/..

14

Impact of PET‐2 guided treatment de‐escalation on time‐to‐r..:

Ferdinandus, J. ; Müller, H. ; Damaschin, C....
Hematological Oncology. 41 (2023) S2 - p. 355-356 , 2023

Link: https://doi.org/10.1002/..

15

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN..:

Shadman, M. ; Munir, T. ; Roback, T....
Hematological Oncology. 41 (2023) S2 - p. 235-238 , 2023

Link: https://doi.org/10.1002/..